Novel C-terminal Hsp90I with isoform selectivity will function as selective anti-cancer agents in the treatment of lung cancers

HSP90, a heat shock protein, protects cancer cells from chemotherapy. Dr. Vielhauer’s laboratory is developing novel targeted therapy that selectively blocks HSP90 and kills lung cancer cells.